Guillem Argilés

7.2k total citations · 1 hit paper
95 papers, 2.5k citations indexed

About

Guillem Argilés is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Guillem Argilés has authored 95 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Guillem Argilés's work include Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer Genomics and Diagnostics (20 papers). Guillem Argilés is often cited by papers focused on Colorectal Cancer Treatments and Studies (57 papers), Cancer Treatment and Pharmacology (28 papers) and Cancer Genomics and Diagnostics (20 papers). Guillem Argilés collaborates with scholars based in Spain, United States and France. Guillem Argilés's co-authors include Josep Tabernero, Élena Elez, Takayuki Yoshino, Dirk Arnold, Ramón Salazar, Julien Taı̈eb, Timothy Iveson, Daniel Hochhauser, Pierre Laurent‐Puig and Erika Martinelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Guillem Argilés

91 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2020 736 citations Guillem Argilés, Josep Tabernero et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Guillem Argilés

Since Specialization

Citations

This map shows the geographic impact of Guillem Argilés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillem Argilés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillem Argilés more than expected).

Fields of papers citing papers by Guillem Argilés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillem Argilés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillem Argilés. The network helps show where Guillem Argilés may publish in the future.

Co-authorship network of co-authors of Guillem Argilés

This figure shows the co-authorship network connecting the top 25 collaborators of Guillem Argilés. A scholar is included among the top collaborators of Guillem Argilés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillem Argilés. Guillem Argilés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors 2024 ·Journal of Clinical Oncology ·Paul Johannet, (unknown), (unknown), (unknown), Henry Walch, Benoı̂t Rousseau, Guillem Argilés, Oliver Artz, Mitesh Patel, Andrea Arfè, Andrea Cercek, Rona Yaeger, (unknown), Nikolaus Schultz, Luis A. Díaz, Michael B. Foote	5
2	A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors 2024 ·ESMO Open ·Heinz‐Josef Lenz, Guillem Argilés, Maja J.A. de Jonge, Rona Yaeger, Takefumi Doi, (unknown), Ferry A.L.M. Eskens, (unknown), (unknown), (unknown), Loes M. Pronk, Josep Tabernero	5
3	Analysis of Shared Variants between Cancer Biospecimens 2024 ·Clinical Cancer Research ·Michael B. Foote, James R. White, Walid K. Chatila, Guillem Argilés, Steve Lu, Benoı̂t Rousseau, Oliver Artz, Paul Johannet, Henry Walch, Mitesh Patel, Michelle F. Lamendola-Essel, David Casadevall, (unknown), (unknown), Rona Yaeger, Andrea Cercek, Clara Montagut, Michael F. Berger, Nikolaus Schultz, Luis A. Díaz	0
4	Facts and Hopes in Colorectal Cancer Immunotherapy 2023 ·Clinical Cancer Research ·Michael B. Foote, Guillem Argilés, Benoı̂t Rousseau, Neil H. Segal	5
5	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study 2022 ·British Journal of Cancer ·Eric Van Cutsem, Iwona Danielewicz, Mark Saunders, Per Pfeiffer, Guillem Argilés, Christophe Borg, Rob Glynne‐Jones, Cornelis J.A. Punt, Agnès J. van de Wouw, М. Yu. Fedyanin, Daniil Stroyakovskiy, Hendrik Kroening, Pilar García‐Alfonso, Harpreet Wasan, Alfredo Falcone, Ronan Fougeray, Anton Egorov, Nadia Amellal, Vladimir Moiseyenko	9
6	Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study 2021 ·ESMO Open ·Roberto Bordonaro, Aitana Calvo, A. Auriemma, Antoine Hollebecque, Gábor Rubovszky, Mark Saunders, Zsuzsanna Pápai, Gerald W. Prager, Alexander Stein, Thierry André, Guillem Argilés, Antonio Cubillo, Laëtitia Dahan, Julien Edeline, (unknown), Valérie Cattan, Ronan Fougeray, Nadia Amellal, Josep Tabernero	11
7	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up breakdown → 2020 ·Annals of Oncology ·Guillem Argilés, Josep Tabernero, Roberto Labianca, Daniel Hochhauser, Ramón Salazar, Timothy Iveson, Pierre Laurent‐Puig, Philip Quirke, Takayuki Yoshino, Julien Taı̈eb, Erika Martinelli, Dirk Arnold	736
8	Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses 2019 ·Clinical Colorectal Cancer ·Heinz‐Josef Lenz, Guillem Argilés, Takayuki Yoshino, Sara Lonardi, Alfredo Falcone, María Luisa Limón, Alberto Sobrero, Claudia Hastedt, Barbara Peil, Florian Voß, Ingolf Griebsch, Eric Van Cutsem	6
9	Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) 2019 ·Annals of Oncology ·Guillem Argilés, (unknown), Manuel Valladares‐Ayerbes, (unknown), Cristina Grávalos, Pilar Alfonso, Catarina Santos, (unknown), Javier Sastre, Manuel Benavides, (unknown), Fotios Loupakis, Mercedes Rodríguez Garrote, Fernando Rivera, Richard M. Goldberg, Alfredo Falcone, Jaafar Bennouna, Fortunato Ciardiello, Josep Tabernero, Enrique Aranda	15
10	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer 2019 ·European Journal of Cancer ·Guillem Argilés, Thierry André, Antoine Hollebecque, Aitana Calvo, Laëtitia Dahan, Andrés Cervantes, Catherine Leger, Nadia Amellal, Ronan Fougeray, Josep Tabernero	8
11	ESMO Leaders Generation Programme: an alumni insight 2018 ·ESMO Open ·Leticia De Mattos‐Arruda, Carmen Criscitiello, Matteo Lambertini, Guillem Argilés	1
12	Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer 2018 ·ESMO Open ·Guillem Argilés	1
13	Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability 2018 ·Annals of Oncology ·(unknown), Alonso García-Ruiz, Juan Martín-Liberal, Cinta Hierro, Mora Amat, Cristina Viaplana, (unknown), María Vieito, Irene Braña, (unknown), (unknown), (unknown), Guillem Argilés, Mafalda Oliveira, E. Felip Font, Eva Muñoz‐Couselo, Josep Tabernero, Rodrigo Dienstmann, Elena Garralda	5
14	Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study 2018 ·Annals of Oncology ·Eric Van Cutsem, Takayuki Yoshino, Heinz‐Josef Lenz, Sara Lonardi, Alfredo Falcone, (unknown), Mark Saunders, Alberto Sobrero, Y.S. Park, (unknown), Yong Sang Hong, Jiří Tomášek, Hiroya Taniguchi, Fortunato Ciardiello, James D. Stoehr, Zohra Oum'Hamed, Soetkin Vlassak, Matus Studeny, Guillem Argilés	49
15	Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies 2016 ·Molecular Cancer Therapeutics ·Daniel Azuara, Cristina Santos, Adriana López‐Doriga, Julieta Grasselli, Marga Nadal, Xavier Sanjuán, (unknown), Joana Vidal, Robert Montal, Vı́ctor Moreno, Beatríz Bellosillo, Guillem Argilés, Élena Elez, Rodrigo Dienstmann, Clara Montagut, Josep Tabernero, Gabriel Capellá, Ramón Salazar	12
16	Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer 2015 ·Cancer Discovery ·Rodrigo Dienstmann, Amita Patnaik, Rocio García‐Carbonero, Andrés Cervantes, Marta Benavent, Susana Roselló, Bastiaan B.J. Tops, Rachel S. van der Post, Guillem Argilés, (unknown), (unknown), (unknown), Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Stephan Braun, Eric Van Cutsem, Anthony W. Tolcher, Josep Tabernero	58
17	Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer 2015 ·Clinical Cancer Research ·Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P. Tenbaum, Guillem Argilés, Rodrigo Dienstmann, (unknown), Ginevra Caratù, Judit Matito, Daniel Silberschmidt, Jordi Rodón, Stefania Landolfi, Aleix Prat, Eloy Espín, R. Charco, Paolo Nucíforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Héctor G. Pálmer	147
18	A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies 2015 ·Clinical Cancer Research ·Shilpa Gupta, Guillem Argilés, Pamela N. Münster, Antoine Hollebecque, Olav Dajani, Jonathan D. Cheng, Ruixue Wang, Ann Swift, Alessandra Tosolini, Sarina A. Piha‐Paul	27
19	Current and advancing treatments for metastatic colorectal cancer 2015 ·Expert Opinion on Biological Therapy ·Enrique Sanz‐García, Julieta Grasselli, Guillem Argilés, (unknown), Josep Tabernero	31
20	Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT Inhibitor) in Patients with Advanced Breast Cancer with PI3K Pathway Dependence 2014 ·Annals of Oncology ·Supriya Gupta, (unknown), Antoine Hollebecque, Guillem Argilés, Tormod Kyrre Guren, J. Cheng, (unknown), A. Swift, Alessandra Tosolini, Sarina A. Piha‐Paul	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact